a public good project by the
Synthesis
Company
of California

© 2026

Andrew F. Wilks | doi.page

0 works0 citations0 h-index

Andrew F. Wilks

Boston University(US)Boston Medical Center(US)

Publications by Year

Research Areas

Cytokine Signaling Pathways and Interactions, Angiogenesis and VEGF in Cancer, Monoclonal and Polyclonal Antibodies Research, RNA Research and Splicing, HER2/EGFR in Cancer Research

Most-Cited Works

→ Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4)(1998)1,203 cited
→ Association of Transcription Factor APRF and Protein Kinase Jak1 with the Interleukin-6 Signal Transducer gp130(1994)821 cited
→ The protein tyrosine kinase JAK1 complements defects in interferon-α/β and -γ signal transduction(1993)770 cited
→ Activation of the pseudokinase MLKL unleashes the four-helix bundle domain to induce membrane localization and necroptotic cell death(2014)588 cited
→ Polypeptide signalling to the nucleus through tyrosine phosphorylation of Jak and Stat proteins(1993)511 cited
→ Two novel protein-tyrosine kinases, each with a second phosphotransferase-related catalytic domain, define a new class of protein kinase.(1991)503 cited

→ Two putative protein-tyrosine kinases identified by application of the polymerase chain reaction.(1989)

424 cited

Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence.(1996)

JAK2, a third member of the JAK family of protein tyrosine kinases.(1992)

→ Dissecting Specificity in the Janus Kinases: The Structures of JAK-Specific Inhibitors Complexed to the JAK1 and JAK2 Protein Tyrosine Kinase Domains(2009)265 cited